New drug nemolizumab tested for rare skin disease
NCT ID NCT05214794
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested the drug nemolizumab in 6 people with systemic sclerosis, a rare disease that causes skin thickening. The goal was to see if the drug could improve skin symptoms and to check its safety. Participants received injections of nemolizumab, and doctors measured skin thickness over 24 and 52 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- nemolizumab
- What this could lead to
- If it works, this could point toward a treatment to reduce skin thickening in systemic sclerosis.
- What could go wrong
- This is a very small, early-phase trial with only 6 participants, so results may not apply widely. The drug may not improve symptoms or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The University of Tokyo Hospital
Tokyo, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immune clues in the blood may foretell heart trouble
- Blood particles may reveal hidden clues to scleroderma complications
- Could a simple injection dissolve painful calcium lumps in rare diseases?
- Finger injections aim to loosen stiff hands in scleroderma
- Continued anifrolumab treatment studied for lupus and related diseases
- Blood thinner may stop autoimmune disease before it starts